Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 76 member A (FAM76A)
- Target
- FAM76A
- Molecular classification
- Other (unclassified nuclear protein; often categorized as a "Protein of unknown function" or "Uncharacterized protein"), Contains a Band7/PHB/SPFH domain (sometimes associated with structural or regulatory roles), Nuclear protein (not a receptor, enzyme, transporter, or ion channel)
01
Overview
Family with sequence similarity 76 member A (FAM76A) is a nuclear-localized protein characterized by a coiled-coil domain and a Band7/PHB/SPFH domain of unknown function. It is broadly conserved among vertebrates and some invertebrates but is absent from fungi, plants, and prokaryotes. FAM76A is predicted to play a role in the regulation of transcription or RNA processing, supported by its nuclear location and association with nuclear speckle targeting motifs. Clinically, increased expression of FAM76A is associated with poor outcomes in ovarian cancer, possibly through interaction with the WTAP–HBS1L/FAM76A axis, and has been identified as a possible prognostic biomarker and therapeutic target in this context. Its precise molecular function and interactions are not fully characterized, and there are currently no drugs targeting FAM76A. Copy number variations disrupting the FAM76A locus have been linked to developmental anomalies, but no therapy-related safety concerns are established.
- Other names
- Protein FAM76AMGC34648FA76AFamily with sequence similarity 76, member AIn C. elegans: K04F10.7
02
Mechanism of action
Not established (no drugs known to target FAM76A directly, so mechanism of action information is unavailable)
03
Biological functions
Possible role in transcription regulation (predicted nuclear localization, presence of nuclear targeting signals, and suggested interaction with RNA processing pathways)Protein desumoylation (potential, based on sequence features)Unknown / other (due to lack of precise functional characterization)
04
Disease associations
Cancer (notably ovarian cancer, where its increased expression correlates with poor prognosis and oncogenic pathways)Neurodevelopmental disorders (copy number variants affect neurodevelopment and growth)Possibly other—unconfirmed roles suggested by gene neighborhood and expression analysis
05
Safety considerations
Unknown / not established (no safety data on therapeutic modulation; gene copy number variants have been associated with developmental delay but not as therapy-induced toxicity)
06
Interacting drugs
None known (no approved or experimental drugs directly targeting FAM76A have been identified in major databases as of 2024)
07
Biomarkers
Overexpression in ovarian cancer has been associated with poor prognosis and may serve as a prognostic biomarker
Beyond the preview
Go deeper on Family with sequence similarity 76 member A (FAM76A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Family with sequence similarity 76 member A (FAM76A).